Jubilant HollisterStier Announces COVID-19 Vaccine Candidate Manufacturing Agreement With Novavax

Jubilant HollisterStier LLC, a wholly owned subsidiary of Jubilant Pharma Limited, announced that it has entered into a non-exclusive manufacturing agreement with Novavax, a biotechnology company developing next-generation vaccines for serious infectious diseases, to provide fill-finish manufacturing services for the production of COVID-19 vaccine candidate NVX-CoV2373.

Under the terms of the agreement, Jubilant HollisterStier’s Spokane, Washington facility has begun production activities of NVX-CoV2373 final drug product intended for commercial distribution in the United States.